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about the reliability of NGS cancer panels. Regarding this issue, 
several working groups, including the College of American 
Pathologists (CAP) or the American College of Medical Genet-
ics and Genomics (ACMG), issued guidelines on NGS clinical 
tests.3,4 Yet, there is no reliable guideline for NGS cancer panel 
tests that accommodates the regulatory environment in Korea. 
Considering that NGS-based testing is rapidly evolving and 
improving, the Molecular Pathology Study Group aimed to 
establish a necessary regulatory framework for clinical NGS 
By virtue of completion of the human genome project, a set of 
technologies that are referred to as next-generation sequencing 
(NGS) has been developed.1,2 Being able to sequence millions of 
short fragments of DNA simultaneously, NGS technologies 
have achieved unprecedented high-throughput and low per-
base cost. The combination of its powerful analytic performances 
and the rapidly dropping cost of NGS rapidly brought NGS 
to clinic. However, the amount and complexity of sequencing 
data, especially for cancer genome sequencing, raised concerns 
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Next-generation sequencing (NGS) has recently emerged as an essential component of person-
alized cancer medicine due to its high throughput and low per-base cost. However, no sufficient 
guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. 
To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled 
by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel 
testing procedures and requirements for clinical implementation of NGS. This consensus stan-
dard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS 
laboratories. The laboratory guidelines part addressed several important issues across multi-
step NGS cancer panel tests including choice of gene panel and platform, sample handling, nu-
cleic acid management, sample identity tracking, library preparation, sequencing, analysis and 
reporting. Requirements for clinical NGS tests were summarized in terms of documentation, vali-
dation, quality management, and other required written policies. Together with appropriate pa-
thologist training and international laboratory standards, these laboratory standards would help 
molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In 
this way, the oncology community would be able to help patients to benefit more from personal-
ized cancer medicine.
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tests without inhibiting further upgrade of NGS-based technol-
ogies.
Unlike traditional single gene-based sequencing tests, the 
NGS cancer panel involves a complex two-step process: (1) wet 
bench process and (2) bioinformatics analysis of sequence data. 
The wet bench process includes the handling of patient samples, 
extraction of nucleic acids, fragmentation and barcoding, target 
enrichment, adaptor ligation, library preparation, and genera-
tion of sequence reads. Bioinformatics analysis includes mapping 
sequence reads to the human reference genome, variant calling, 
annotation, and reviewing data in the right clinical context. We 
regarded these two steps as distinct processes requiring separate 
standards because some laboratories might use external facilities 
to perform either portion of the NGS cancer panel tests. This 
report aims to provide a general guidance for developing more 
detailed NGS checklists, that will be done by a separate working 
group involving regulatory agencies in the near future.
LABORATORY GUIDELINES 
FOR NEXT-GENERATION SEQUENCING 
CANCER PANEL TESTS
Choice of genes to be tested and test platforms
Traditionally, only a limited number of clinically validated 
predictive or prognostic biomarkers have been approved as 
clinical tests. However, accumulating genomic data obtained 
from multiple tumor types and expansion of genome-based 
clinical trials suggest that many of the future anti-cancer treat-
ments and clinical trials will require comprehensive diagnostic 
panels that allow the detection of multiple mutations at the 
same time. Such tests might involve either probe-based capture 
or primer-based amplification for the enrichment of genomic 
regions to be tested. 
The number and scope of genes to be tested depend on the 
purpose of the test. If the purpose is limited to companion diag-
nostics for current standard care, the number of genes would 
be very limited. However, if there is a need for clinical trials for 
which NGS-based tests are required to stratify patients, a broader 
range of genes should be interrogated. In this context, the cur-
rently used cancer panel tests are mainly focused on clinically 
actionable genomic alterations at selected protein-coding regions 
that are defined by the availability of approved drugs and pathog-
nomonic molecular features. However, there is an increasing need 
for adding genomic alterations associated with resistance to 
molecularly targeted therapies or predicted response to investi-
gational drugs. Furthermore, genomic data could be used to 
refine pathological diagnosis. For example, mutations in IDH1 
or IDH2 and co-deletion of chromosome 1p and 19q are already 
incorporated in recently revised pathological diagnosis of diffuse 
glioma.5
There are several NGS platforms such as Illumina, Ion Tor-
rent, and Roche 454, and all of which have been reported to be 
as reliable as the current standard genotyping tools at least for 
the important cancer genes provided that laboratories perform 
adequate quality control.6-8 Thus, pathology laboratories may 
choose their preferred platforms based on their individual 
requirements, such as expected sample status (i.e., small biopsies, 
resected tissue samples, or liquid biopsies, etc.), expected num-
ber of samples, and/or types of variants to be analyzed (e.g., copy-
number analysis might be limited in platforms that use primer-
based amplification during target enrichment). It is important 
for laboratories to be aware of platform characteristics and perform 
adequate quality controls depending on the platform character-
istics.
Specimen handling
Sample transportation, receipt, and storage
Adequate processing of tissue samples is essential in a reliable 
NGS cancer panel test. Required specimen handling procedures 
are nearly the same as those required for traditional single-gene 
tests. Briefly, the quality and the amount of neutral buffered 
formalin relative to the size of the specimen should be monitored. 
The time interval from specimen acquisition to fixation should 
be minimized, and optimal fixation duration should be moni-
tored.9 The optimal fixation duration depends on the dimension 
of each sample because formalin penetrates tissue at a rate of 
approximately 1 mm per hour. The rule of thumb for recom-
mended fixation duration for surgically resected specimen is 24 
hours.10
Morphological assessment and designation of ideal tumor area
Correct pathologic diagnosis and assessment of the fraction of 
neoplastic cell nuclei in tumor area by pathologists are crucial 
for the interpretation of NGS results. Once the diagnosis and 
tumor purity are established, it is strongly recommended that 
the pathologists circle an area from which nucleic acid is extracted 
so that neoplastic cells are enriched to the appropriate level of 
tumor purity. The minimum requirement of tumor purity can 
be established in the initial validation of test performances (see 
“Validation” section). The estimated tumor purity of a selected 
area should be documented. When tumor purity is assessed, the 
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pathologists should be aware of the fact that the relative number 
of tumor cell nuclei reflects tumor purity rather than occupied 
tumor area. Thus, an area with heavy inflammatory cell infil-
tration should be avoided (Fig. 1A, B). Also, to ensure DNA 
quality, pathologists should try to avoid necrotic areas (Fig. 1C) 
and areas with extensive extracellular mucin (Fig. 1D). 
Nucleic acid extraction, quantification, and storage
For clinical tests, DNA extraction kits should have a high 
level of performance specification to obtain DNA of sufficient 
quality and quantity for intended NGS tests from formalin-
fixed paraffin embedded (FFPE) samples. In addition, DNA 
extraction procedures should have appropriate mechanisms by 
which sample contamination or misidentification could be 
avoided. Several commercially available kits that use silica-based 
or magnetic bead–based extraction protocols meet such require-
ments. 
A major cause of sequence artifacts is deamination of cytosine 
resulting in C to T transitions during amplification.11-14 Formalin 
fixation and longer storage period contribute to this process.15 
Since those sequence artifacts are usually present at a very low 
frequency, such artifacts are unlikely to affect test results if suffi-
cient amounts of unique DNA molecules are available. How-
ever, if the DNA input amount is too small or if the purpose is 
to detect variants with low allelic fraction, these artifacts would 
be a problem. In addition, amplicon-based methods are more 
susceptible to these artifacts than hybridization capture-based 
methods.11 Thus, laboratories may choose DNA extraction proto-
cols with enzymatic removal of uracil-containing templates when 
they interrogate FFPE samples with highly fragmented DNA or 
with low tumor purity by amplicon-based methods. In the case 
of decalcified specimens, DNA quality or quantity is inferior to 
Fig. 1. Varying tissue conditions to be considered for next-generation sequencing analysis. (A) Gastric carcinoma with lymphoid stroma with 
acceptable tumor content although many intraepithelial lymphocytes are seen. (B) The same case as (A) but this area has unacceptable tumor 
content due to heavy lymphoid cell infiltration. (C) This poorly differentiated carcinoma shows extensive necrosis. (D) Mucinous adenocarci-
noma of the colon shows a large area of extracellular mucin. 
B
D
A
C
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those of the specimens without decalcification. Regarding this, 
it has been reported that a decalcification protocol involving eth-
ylenediaminetetraacetic acid might be better than that involving 
hydrochloric acid in terms of usable nucleic acid for subsequent 
NGS analysis.16
Quantitation of extracted nucleic acids can be done by Nano-
Drop, Qubit, or the Picogreen method. Among them, Nano-
Drop is not recommended because it also detects nucleic acids 
that are not suitable for downstream analyses. Nucleic acids 
should be stored under highly controlled conditions in order to 
maintain sample identity and integrity. Extracted DNA is to be 
stored at –20˚C and RNA at –80˚C. Sequencing libraries and 
polymerase chain reaction (PCR) products may be stored in 
–20˚C but should be separated from pre-amplification materials to 
prevent them from contaminating pre-amplification materials.
Sample identity tracking
Like other single gene–based tests, verification of sample 
identity is the most basic and important aspect in clinical NGS 
test. The NGS cancer panel tests involve many steps, making 
them inherently subject to sample mix-up or swapping. Thus, 
test procedures should have an appropriate system to minimize 
such critical events. For example, panels could be designed to 
include a number of single nucleotide polymorphism (SNP) 
markers that allow molecular barcoding of patient samples17 so 
that sample identity can be traced. In addition, an electronic 
laboratory information management system could be useful for 
this purpose. With any tool in place, it is important to enable 
end-to-end sample tracking in clinical NGS cancer panel tests.
Library preparation
Library preparation is the step where extracted nucleic acids 
are prepared for the sequencing reaction. It involves DNA frag-
mentation, adaptor ligation, and enrichment of the target of 
interest. Target enrichment can be done either by an amplicon-
based approach or by hybridization-based capture. Molecular 
barcodes are usually introduced to enable sample identification 
and pooling of multiple samples in a single flow cell lane. To 
avoid contamination, all steps before amplification should be 
done in a separate space. In addition, extra-caution should be in 
place during sample transportation from pre-PCR area to post-
PCR area. After library preparation, appropriate quality controls 
should be applied to determine whether the rest of the proce-
dures should be continued. Quality controls include quantita-
tion, fragment size analysis, and quantitative PCR using adaptor 
sequences for priming.
Data analysis of sequence reads
Bioinformatics pipelines used for the analysis of NGS data 
consists of multiple steps, such as de-multiplexing, read align-
ment, de-duplication, base calibration, variant calling, filtering, 
and annotation. Currently, no single “gold-standard” algorithm 
exists. Therefore, laboratories should choose the most suitable 
algorithm for the types of variants to be reported and optimize 
them. In the absence of a “gold standard,” it is important to vali-
date the analytic performance of the bioinformatics pipelines.18-20 
It is also important to make sure that all versions of algorithms 
are traceable and properly updated (see “Validation” section).
Sequencing read 
The initial step after sequencing includes converting the base 
intensities in a sequencer to digital-level nucleotide sequences, 
called FASTQ. Although the types of signals differ among var-
ious sequencing platforms, most have their internal software for 
translating base calling into the compressed and de-multiplexed 
FASTQ files. The nucleotides in FASTQ have corresponding 
base quality scores that are in a form of logarithmic scales indi-
cating the probabilistic confidence level of the bases. Appropri-
ate quality control should be done to confirm the general integ-
rity of the sequencing data, such as the total number of bases, 
sequence contents (including GC contents), per base sequence 
quality, etc. Read trimming is recommended if the base quality 
or composition does not meet the quality control threshold that 
each laboratory has empirically set up or that the sequencer 
manufacturer has recommended. 
Alignment
This step is to find where the short read sequences are located. 
In general, single or pair-end reads are first aligned (mapped) to 
a human genome reference. It is essential to include the version 
of the human reference sequence in the clinical report. Since 
poorly mapped sequences may lead to compromise the reliabili-
ty of called variants, especially in solid tumors with low tumor 
content, sequencing reads should be filtered based on mapping 
quality score so that only confidently mapped reads are pro-
cessed further. After the initial mapping, read duplicates should 
be removed, because unwanted clonal amplification of reads 
with sequence artifacts may lead to false-positive variant calls. 
Alignment is often challenging when the sequence reads come 
from genomic regions having large insertions or deletions, repeti-
tive regions, pseudogenes, or homologous genes because there 
can be several other similar-looking genomic regions across the 
reference genome. Realignment using known references that 
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have the suspected insertions or deletions may be necessary in 
such cases. 
Variant calling: single nucleotide variation, insertion/deletion, 
copy-number variation, and translocation
Somatic variants can be identified by subtracting variants 
found in non-neoplastic cells from those found in cancer. If a 
laboratory chooses not to sequence the corresponding normal 
samples, it should be noted that some germline variations might 
exist in the result. Laboratories should consider the implementa-
tion of modular analysis pipelines, in which different algorithms 
or settings are used to call different types of variants: single nucle-
otide variations (SNVs), insertion/deletion (Indels), copy-number 
variations (CNVs), and translocations. 
SNV/Indel
The quality of variant calls is strongly related to the quality 
of alignment. The key challenge of variant calling is to distin-
guish real variants from sequencing errors. In general, the more 
times the variant is sequenced, the more reliable the variant call 
is. The minimum depth of coverage depends on the required 
sensitivity of the intended assay, the sequencing platform and 
the types of mutations to be detected. Although sensitivity is 
increased in proportion to sequencing depth, false-positive calls 
may also be increased especially in cases with low tumor content. 
There are various reasons for false-positive variant calls; they often 
result from PCR errors, sequencing errors, mis-mapped reads on 
repetitive sequences or homologous regions and so forth. Because 
each variant calling algorithm uses different strategies to filter 
out false calls, different algorithms sometimes generate discrepant 
results. Thus, laboratories should find optimal parameter settings 
during assay development and validation to minimize algorithm-
dependent result variability. 
Reliable identification of Indels is particularly challenging 
because sequence reads containing this type of variants are not 
often accurately mapped. Thus, the sensitivity and specificity 
for this type of variants is often reduced. With regard to this, 
laboratories should identify clinically important Indels and vali-
date assay performances to establish reasonable sensitivity and 
positive predictive value for the identification of those Indels. 
Due to the high rate of false-positives, manual review by using 
visualization tools and comparison with the same regions in 
other samples on the same run is recommended for all Indel calls.
Copy-number variation
The reliable identification of CNV is quite difficult in NGS 
cancer panel sequencing because of the uneven target coverage 
related to hybridization capturing steps, the absence of matched 
normal data, or the lack of coverage uniformity.21 Although 
algorithms for detecting CNV in targeted NGS tests are improv-
ing,22 the inherent limitations in cancer panel sequencing of 
clinical FFPE samples require robust validation of test perfor-
mance. This type of validation can be done by testing character-
ized cancer cell lines or clinical samples with known CNV profiles 
(see “Validation” section),23 although there is no agreement upon 
the minimal number of samples for appropriate validation. 
Translocation
Translocation can be identified based on the DNA level, using 
discordant or split sequencing reads. However, the inherent 
limitations of short-reads in terms of alignment can result in 
many false positive calls. Therefore, the test performance should 
be appropriately validated using reference materials with known 
translocations across targeted genomic regions that have been 
confirmed by the current gold standard. Furthermore, it is highly 
recommended that all translocation calls be manually reviewed 
by using genome visualization tools such as the Integrative 
Genomics Viewer. Finally, it should be noted that a translocation 
can be missed if the breakpoint of fusion (may be somewhere in 
the introns not covered by the panel) is not included in targeted 
genomic regions, even though protein-coding regions of the 
translocation partners are included in the panel. 
Variant annotation and filtering
Variant annotation determines if a sequence variant is real 
and provides predicted resulting amino acid changes. To identify 
true somatic variants, false variants should be properly filtered. 
Important sources of false variants include cytosine deamina-
tion, amplification errors, and sequencing errors. Cytosine deami-
nations are introduced ex vivo; these variants are not copied to 
the opposite strand, meaning that the artifacts are only present 
on one strand. To facilitate the detection of cytosine deamination 
artifacts, laboratories may use techniques such as molecular inver-
sion probe and HaloPlex and Duplex sequencing, to enrich and 
sequence both the sense and antisense DNA strands.24 Amplifi-
cation errors can be introduced due to DNA polymerase errors 
during amplification steps of library enrichment. These errors 
might be minimized by the application of unique barcodes 
to individual DNA molecules during library enrichment. If the 
same variant is detected in multiple unique molecules, the variant 
might be real because it is unlikely that individual molecules 
acquire the same polymerase error during amplification. Sequenc-
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ing errors are highly dependent on the sequencing platform and 
sequencing chemistry. The ability to call SNVs and Indels is 
known to be similarly accurate for data generated on the PGM 
and Illumina platform, provided that there is sufficient coverage.24
Interpretation of computational output
Depending on the types of variants (e.g., missense, nonsense, 
etc.) and the types of genes (e.g., hotspots in oncogenes vs ran-
domly distributed mutations in tumor suppressor genes), inter-
pretation of detected variants can be simple or quite compli-
cated. Basically, the ACMG strongly recommends that inter-
pretation is performed by trained staffs such as clinical molecular 
geneticists or molecular pathologists.4 A multi-disciplinary 
sequencing data analysis team with various scientific back-
grounds including clinical oncology, genomics, bioinformatics, 
and pathology, is recommended for accurate interpretation.
For variants that are not hotspot mutations, germline vari-
ants should be excluded first. Since most cancer panel tests do 
not analyze matched non-neoplastic tissue, laboratories should 
prepare mechanisms to filter out potential germline variants 
based on the genetic polymorphism data on the population to 
which the tested patient belongs. In most instances, laborato-
ries use public databases on germline polymorphism such as the 
1000 Genomes Project, ExAC, or dbSNP (Table 1), but ideally, 
these data should be derived from the same ethnic group as the 
tested patient. 
Since the clinical and biological significance of cancer-related 
genomic variants are increasingly characterized, many variants 
detected in most cancer panel tests have related information 
in public databases (see “Reporting” section for details). How-
ever, previously uncharacterized variants may also be detected 
considering the characteristics of NGS tests. Potential biological 
significance, or pathogenicity, could be inferred from the archived 
genotype-phenotype correlation data such as ClinVar, Human 
Gene Mutation Database, and Leiden Open Variation Database 
(Table 1). In addition, the in silico prediction of functional 
impacts is available in dbNSFP or Ensembl Variant Effector 
(Table 1). Since no single database is perfect, it is essential to refer 
to multiple resources for appropriate interpretation. Finally, 
knowledge about variants will be continuously improved with 
the accumulation of each lab’s experiences and feedbacks from 
clinicians. 
Reporting
General format
Reporting of NGS cancer panel test results should follow the 
general professional organizations’ recommendations and guide-
lines.25 There are two major essential parts of a report: proper 
patient identification and detected actionable variants. The 
patient identification part is the same as that in the current stan-
dard single gene-based tests, but the detected variant part is more 
complex and sophisticated in clinical NGS cancer panel tests 
because typical NGS cancer panel tests detect multiple variants 
at the same time. The clinical NGS report should include the 
essential information listed in Table 2, and the most pertinent 
information, such as actionable variants and a critical summary 
of those variants, should be placed in a clearly visible section on 
the first page. Detected sequence variants should be annotated 
in concordance with the Human Genome Variation Society 
mutation nomenclature and the version of the human reference 
sequence to which sequence reads were aligned should also be 
Table 1. Useful online resources for variant interpretation
Subject Database/Algorithm URL
Germline polymorphism dbSNP, dbVar
1000 Genomes Project
ExAC
https://www.ncbi.nlm.nih.gov/projects/SNP/
http://browser.1000genomes.org/
http://exac.broadinstitute.org
Cancer-specific somatic variants COSMIC
cBioPortal
My Cancer Genome
CIViC
Personalized Cancer Therapy, MD Anderson Cancer Center
http://cancer.sanger.ac.uk/cosmic
http://www.cbioportal.org/
https://www.mycancergenome.org/
https://civic.genome.wustl.edu/#/home
https://pct.mdanderson.org/#/
Genotype-phenotype association,
  not limited to cancer
ClinVar
Human Gene Mutation Database
Leiden Open Variation Database
https://www.ncbi.nlm.nih.gov/clinvar/
http://www.hgmd.cf.ac.uk/ac/index.php
http://www.lovd.nl/3.0/home
In silico functional prediction dbNSFP (pre-computed in silico functional prediction and
  annotation of non-synonymous SNVs)
Ensembl Variant Effector Predictor
http://sites.google.com/site/jpopgen/dbNSFP 
http://www.ensembl.org/info/docs/tools/vep/index.html
This list is not comprehensive and only provides some examples. All websites were last accessed on January 3, 2017. 
ExAC, Exome Aggregation Consortium; COSMIC, Catalog of Somatic Mutations in Cancer; CIViC, Clinical Interpretations of Variants in Cancer; NSFP, non-
synonymous functional prediction; SNV, single nucleotide variation.
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included in the report. Variants, which are not clinically action-
able but are potentially useful for future practice, might follow 
the actionable variants. Then, detailed information about the 
detected variants (see the “Interpretation” section) and essential 
technical information, such as genes or genomic regions included 
in the panel and key quality control metrics, may be listed. Inclu-
sion of granular details of technical information is not recom-
mended, but a description of how clinicians can obtain the details 
may be included.26
Presentation of detected variants and clinical translation
Since typical cancer panel results include several cancer-re-
lated genomic variants with different levels of clinical or biological 
evidences, variants should be classified and reported according to 
the level of evidences. Several leading institutions use their own 
variant classification system and each institution may discuss 
with clinicians about which variant classification system should 
be used. However, a recently published related guideline is a 
good example27: (1) Tier 1, strong clinical significance such as 
Food and Drug Administration (FDA)–approved therapies, 
professional guidelines, prognostic and diagnostic markers 
based on well-powered studies with expert consensus; (2) Tier 2, 
potential clinical significance such as FDA-approved therapies 
for different tumor types, investigational therapies, prognostic 
and diagnostic markers based on small published studies with 
some consensus and preclinical trials or case reports without 
consensus; (3) Tier 3, unknown clinical significance; and (4) 
Tier 4, benign or likely benign. Tier 1 to 3 variants should be 
included in the clinical NGS report in a decreasing order of 
clinical significance and it is not recommended to include Tier 
4 variants in clinical NGS report. 
Interpretation of detected variants in terms of their clinical 
impact and pathogenicity is a daunting task. As mentioned in 
the “Interpretation of computational output” section, many 
information sources such as public databases, published guide-
lines, and computational prediction algorithms should be inte-
grated for proper interpretation. In addition to the previously 
mentioned public databases on germline polymorphism, in silico 
prediction of the functional impacts, genotype-phenotype rela-
tionship, and several cancer-specific mutation databases are 
available online (Table 1). These resources are very useful in the 
interpretation of variants in the context of cancer, but it is impor-
tant to make sure that the database is properly curated, referenced 
and updated in a regular basis. Regarding this, FDA guidance 
suggested that appropriate databases should implement decision 
matrices with published details of each variant’s interpretation 
and have documented standard operating procedures (SOPs) for 
the curation and update of this information.28
When assigning variants to each tier, it is essential that they 
should be interpreted in the context of both variant details (e.g., 
BRAF V600E) and patient tumor type (e.g., malignant mela-
noma vs colorectal cancer). This is because different variants in 
a single gene may have different clinical impacts and the clinical 
significance of a particular variant may vary depending on the 
tumor type. For tier 1 variants, a clear statement on their clinical 
relevance and any appropriate action should be included. Also, 
it might be helpful to clarify the absence of other variants that are 
important in the patient tumor type. For tier 2 variants, advising 
the ordering physician about available clinical trials may be 
useful. In addition, tier information is subject to change as new 
evidences and therapeutic options are continuously emerging.
In cases where only limited interpretation can be made and 
full quality control standards could not be met, it is essential 
that pathologists make a professional judgment on whether the 
Table 2. Information to be included in the clinical NGS report
Element Example
Patient identification Registration number, age, gender, ordering physician
Specimen type FFPE, fresh frozen
Pathologic diagnosis Lung adenocarcinoma, clorectal cancer
Tissue sample identification Specimen number, block number
Important dates Date on reception or on report
Percentage of tumor nuclei of the sample used 30%
Variants found Variant details according to HGVS mutation nomenclature
Version of reference genome used hg19 build 36
NGS method used Amplicon-based or hybridization capture-based
Key quality control metrics Mean target coverage, percentage of selected bases, duplication rate 
Genes or genomic regions included in the panel Exonic regions of gene A, B, C, etc.
Interpretation and summary EGFR L858R variants predict response to EGFR tyrosine kinase inhibitors (Erlotinib or Gefitinib)
NGS, next-generation sequencing; FFPE, formalin-fixed paraffin embedded; HGVS, Human Genome Variation Society; EGFR, epidermal growth factor re-
ceptor.
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result should be reported. Also, any limitation of the analysis 
should be clarified in the report. For example, negative results 
in samples with low neoplastic cell content at near or below the 
established sample rejection criteria should be accompanied by 
a note on potential false negatives. Furthermore, clinical NGS 
laboratories should have clearly defined protocols about when 
additional confirmatory tests should be advised, as well as per-
formance validation data in cases where those confirmatory tests 
are not necessary. 
REQUIREMENTS 
FOR CLINICAL NEXT-GENERATION 
SEQUENCING LABORATORIES
Wet Bench Analytic Process
Documentation
The detailed documentation of SOPs is critical for quality 
assurance of a complex, multi-step wet bench process. All SOPs 
of each step of the wet bench process must be documented so 
that each step can be traced. This includes documentation of all 
methods, reagents, instruments and controls (if applicable). 
Most of the documentations should be similar to those of current 
standard single gene testing, but those specific to NGS testing 
include detailed information regarding captured regions, such 
as genomic coordinates of captured probes and lists of genes and 
target enrichment protocols. Clinical laboratories that process 
different types of samples, such as FFPE samples or blood, 
should establish SOPs for each validated sample type. Metrics 
for quality control to assess run status must also be documented. 
Examples include mean target coverage, percentage of reads 
that map to target regions, and the fraction of bases meeting 
specified quality and coverage thresholds. Laboratories must 
define and document acceptance or rejection criteria for each 
step of the wet bench process, such as DNA extraction, library 
preparation, and sequencing.
Validation
Before testing patient samples, clinical NGS laboratories 
must establish the analytical validity of the intended tests. If 
the intended test is approved by the Ministry of Food and Drug 
Safety (MFDS), laboratories can verify the performance specifi-
cations established by the manufacturer. If the intended test is 
not approved by the MFDS, i.e., a laboratory-developed test, 
laboratories must establish performance characteristics such as 
accuracy, precision, sensitivity, specificity, and reportable range. 
Because NGS cancer panel tests involve complex, multistep 
processes, each step needs to be empirically optimized to deter-
mine optimal assay conditions. Once those optimizations are 
done, an analytic validation should be performed for a whole 
test in a “beginning to end” fashion. Test performance should 
be separately validated for different types of samples, such as 
FFPE or blood. 
For “beginning to end” validation, a number of samples 
should be analyzed to assess the test performance. There is no 
general agreement on how many samples are required for this 
type of validation. With regard to this issue, the CAP concluded 
that adding a minimum number of samples for validation is 
premature given the ongoing evolution of NGS technologies 
and the diversity of diagnostic applications.3 Literature review 
revealed that the sample number for validation varied with a 
range of 20–80 samples.29-32 The minimum number of samples 
needed for an appropriate validation might be affected by the 
size of the test, i.e., a larger gene panel will require more exten-
sive validation, and by the range of samples to be tested, i.e., 
FFPE samples with variable tumor content. Here, we suggest 
the general principles of validation in terms of several important 
analytic performance parameters.
Considering the inherent characteristics of NGS cancer panel 
tests, it is important to evaluate as many different genomic regions 
as possible because sequence context can influence sequencing 
results. In addition, laboratories should determine analytic per-
formances for all variant types relevant to the intended test (e.g., 
SNV, Indel, CNV, and translocations). Since NGS-based tests 
interrogate multiple variants at the same time, the validation of 
test performances involves two parts: method-specific (detection 
of as many variants as possible in a single sample) and analyte-
specific (detection of a certain genomic variant in multiple 
samples). Laboratories can establish the test performances by 
combining those two approaches.
Accuracy validation is a “method-specific” way of validation. 
For this type of validation, laboratories might use well-charac-
terized cancer cell line samples to interrogate whether the intended 
test accurately detects all known variants within the genomic 
regions covered by the panel. In this case, reference cell line samples 
should be periodically monitored for identity and passage number 
to prevent a significant genetic drift. In addition, laboratories 
might use well-characterized HapMap samples (NA12878 and 
NA19240), variants of which are readily available on the 
web.33,34 Details of available reference materials are summarized 
in Table 3. Evaluation of these reference samples might be quite 
useful to validate the accuracy across a wide range of genomic 
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regions.23 During this type of validation, an adequate depth of 
coverage threshold35 necessary to accurately call all expected 
variants can be empirically established by plotting false-posi-
tives and false-negatives as a function of coverage.
Analytic sensitivity can be evaluated by comparing NGS test 
results with the current gold standard test results for known 
genetic variants in reference materials. To this end, laboratories 
may use historical controls such as accumulated clinical samples 
with well-characterized genomic variants by gold standard 
methods, provided that the gold standard tests were done in an 
appropriately accredited environment. 
Analytic specificity is theoretically calculated by determining 
the fraction of test negatives (wild type sequence calls by the 
intended test) per true-negatives (samples that are known to 
have wild type sequences by the gold standard method). How-
ever, this concept often does not work well for NGS-based tests 
because too many potential variants are included in typical cancer 
panels. For most laboratories, it might be reasonable to lever-
age specificity by determining the average number of false-pos-
itive calls for the regions tested in a number of well-character-
ized clinical samples. 
The limit of detection can be determined by cell line “mixing” 
experiments, in which a cell line with known genetic variants is 
serially diluted with another cell line without such variants to 
have different mixture ratios, which are then tested to deter-
mine whether the intended test accurately detects all specified 
variants under a certain coverage threshold. Alternatively, labo-
ratories may determine the limit of detection by using the 
HapMap samples (NA12878 and NA19240) mentioned earlier 
by mixing them in various ratios and interrogating variants 
that differ between the two different HapMap samples. 
Precision (repeatability for intra-run and reproducibility for 
inter-run variability) can be determined by repeating the same 
samples in the same run (repeatability) or by repeating the same 
sample in a different run (on a different day by a different operator). 
Ideally, testing at least three samples is recommended to ade-
quately establish precision adequately.3
Any changes to a clinical NGS test, such as changes in instru-
ments, specimen types, reagents, or software, require that perfor-
mance specifications be re-established or be shown to be un-
changed. For example, inclusion of new genes to an existing gene 
panel requires revalidation to make sure that new sequence 
variations are reliably detected without compromising the quality 
of the original assay. The extent of re-validation depends on the 
predicted influence on the test performance related to the change. 
For example, if only the bioinformatics pipeline is updated, it 
may not be necessary to re-validate all steps before data analysis. 
Quality management
Clinical NGS laboratories should establish and follow a quality 
management plan. This plan should be integrated within the 
institution’s overall quality assurance program. Components of 
the NGS quality management program are not much different 
from the traditional single gene-based tests. Once laboratories 
establish an initial validation of test performances, laboratories 
must perform internal quality controls daily and external quality 
controls periodically. Each component of the quality assurance 
program specific to NGS cancer panel tests is discussed in detail 
below.
Internal quality assurance program
Recently, guidelines for quality control and recommenda-
Table 3. Reference materials for NGS: advantages and disadvantages 
Type of material Advantage Disadvantage
Genomic DNA from cell line Large amount available
Similar complexity to patient’s DNA
May have well-characterized variants
May have heterogeneity associated with cell line maintenance
Possible genomic instability over time
Genomic DNA from patient’s 
  sample
Identical condition to real samples Not necessarily renewable
Limited amount of DNA
Well characterized genetic information may be limited
Synthetic DNA Can synthesize a broad range of sequences and
  variations
Can make sequence templates with complex 
  regions (deletions or duplications)
Large amount available
Does not represent actual human cancer genome
May not perform as actual human cancer DNA due to differences 
  in sequence complexity
Will not cover all regions of tested genome
May exhibit higher variant calls due to errors in synthesis
Electronic reference data files Can engineer any wanted sequence files Reference only for data analysis step
Requires many reference datasets to mimick many types
  of sequence data
Data files may not be interoperable among different platforms
Adapted by permission from Macmillan Publishers Ltd: [Nature Biotechnology] Gargis et al. 2012;30:1033-6,36 copyright (2012).
NGS, next-generation sequencing.
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.03.14
200     •  Kim J, et al.
tions for the use of NGS in different applications have been pub-
lished3,4,25,36-42 and are summarized in Table 4. This guidance 
will work as a checklist for each component of the intended 
NGS test and related quality control metrics that require review-
ing in order to feel confident about the quality of results. It is 
impractical to include multiple positive controls with different 
variant types during each run due to unacceptable cost and 
time. Instead, a single characterized external control with 
known variants in each run may be sufficient to demonstrate 
that the procedure is successful.36 Typically, this can be done by 
preparing a number of DNA aliquots from a large FFPE sample 
block whose genome has already been well-characterized genomi-
cally and include those aliquots in each run of patient samples.
External quality assurance program: proficiency testin and 
alternate assessment
The Clinical Laboratory Improvement Amendment (CLIA) 
requires participation in a proficiency testing (PT) program 
twice a year for most clinical tests. For any clinical tests without 
such PT requirements, laboratories must verify test performance 
twice a year.24 Since PT programs specific to NGS cancer panel 
tests do not currently exist, laboratories may verify their test 
performance by using alternate assessment (AA), where de-
identified patient samples are exchanged and re-tested between 
Table 4. Recommended items to check prior to releasing NGS results for diagnostic use and QC metrics
Item Checklist Consequences of non-conformity Improvement suggestions
Tissue sample
  adequacy
Criteria for inadequate specimen
Minimum tumor content
Appropriate sample handling
  including fixation and 
  transportation
Testing inadequate specimens may lead to a
  waste of time and money or depletion of
  available samples.
Inadequate amount or tumor content can lead 
  to false-negative test results.
Check sample adequacy rigorously before testing.
Request further sampling in case of inadequate
  samples.
Nucleic acid
  extraction
DNA quantity and quality in terms 
  of amplifiable DNA
DNA with suboptimal quality may inhibit
  sequencing reaction.
Small amount or fragmentation of DNA may 
  lead to poor quality sequencing data with 
  insufficient or uneven coverage and/or high 
  duplication rate.
Failed samples should be reported as such and
  further material might be requested with specified
  requirement.
Trying another validated extraction method may
  often helps.
Sample
  identification
Sample identity tracking 
  throughout all steps
Misidentification of samples could lead to
  incorrect patient management.
If there is any concern about sample identity,
  starting over from DNA extraction may be
  necessary.
Introduction of polymorphic SNP markers into gene
  panel and running another genotyping method
  with the same marker set might be helpful.
Library
  preparation
Minimum library concentration Poor sequencing library may lead to insufficient 
  or uneven coverage.
Libraries with poor complexity or bias may 
  result in false-negatives. False-positives may 
  also occur due to potential amplification bias.
Consider modification of library preparation method
  or an alternative method to verify any uncertain
  results.
Sequencing Criteria for minimum sequencing
  depth and other quality metrics
  (% reads mapped to target 
  regions, % of targets with 
  specified coverage, duplication 
  rate)
Inadequate coverage is associated with higher
  levels of uncertainty of the test results.
Genomic regions with insufficient local 
  coverage may lead to inaccurate results for 
  variants located in those regions.
Repeat sequencing with existing library or start 
  over from DNA extraction step.
Verification of uncertain results with another method
  may be helpful, especially, in case of actionable
  variants.
Variant
  detection and
  review
Variant allele frequency, local
  sequencing depth and quality 
  score
Presence of the same variant in
  forward and reverse strands
Mapping quality of sequencing 
  reads
Potential sequencing artifacts
Failure to filter out sequencing artifacts may 
  lead to false-positive results.
Clinically important variants may sometimes 
  be missed.
Manually review of clinically important variants even
  if computational algorithms called no mutation on
  them.
Any ambiguous or unexpected results should be
  reviewed by laboratory scientists and pathologists.
Verify variants with another method, if applicable.
Bioinformatics Correct pipeline and version
Appropriate version and build of
  human reference sequence
Cross-contamination?
Using outdated or inadequate software can 
  lead to false-positive or false-negative results.
Update software on a regular basis.
Reporting Endorsed by an authorized
  competent pathologist?
Variants with clinical significance may be 
  reported erroneously, leading to inappropriate 
  treatment.
Responsible pathologists should be given enough
  time and opportunities for education and training.
NGS, next-generation sequencing; QC, quality control.
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different laboratories until formal PT programs are set.24 A 
Korean guideline published by the MFDS follows the same 
principle and requires documentation of all procedures related 
to PT or AA.43 There is no general agreement upon the number 
of reference materials per one round of PT or AA but analysis of 
two samples has been recommended.36
Policies: confirmatory testing, laboratory records, upgrades
As NGS cancer panel tests with appropriate quality controls 
are reported to meet a clinical grade performance,23,44-47 routine 
confirmatory testing is not recommended. However, labora-
tories should have a policy that clearly documents both any 
indication for confirmatory testing as well as any performance 
validation data upon which they decided that such confirmatory 
testing is not necessary. In addition, the CAP is flexible regarding 
the methods used for any needed confirmatory testing.
Keeping comprehensive laboratory records is essential in 
monitoring complex, multi-step NGS cancer panel tests. In 
this regards, such records should be maintained in such a way 
that all detailed information about test procedures including 
reagents, sequencing runs, wet lab, and bioinformatics proce-
dures and responsible technicians is traceable. While all details 
need not be included in the clinical report, laboratories should 
maintain a database from which detailed information regarding 
the analysis of individual specimen can be obtained.
Laboratories must be prepared for upgrades to make sure that 
they are not using obsolete methods. A policy for the upgrade 
of instruments, sequencing chemistries, and reagents or kits, as 
well as subsequent post-upgrade validation of test performances 
should be in place. The policy may include specified intervals 
for upgrade and required validation processes, depending on 
the type or extent of upgrade.
Bioinformatics process
Documentation
Laboratories should document all bioinformatics processes, 
including all data files, variant caller’s parameters, and versions 
of the bioinformatics algorithms. Sources and versions of all 
bioinformatics algorithms should be documented and updated 
properly. Quality control information on bioinformatics analysis, 
such as the cut-off of read depth, base quality score, and mapping 
quality, should also be documented. 
Validation and quality management
General validation principles were already discussed in the 
Validation proportion of the “Wet Bench Analytic Process” 
section. Briefly, for bioinformatics pipelines, laboratories should 
iteratively find parameters for optimal performance of compu-
tational algorithms before applying it to the lab process. Once 
the pipeline is initially validated, variations between sequencing 
runs should be monitored daily. Principles of the quality man-
agement were already discussed in the “Wet Bench Analytic 
Process” section. In short, laboratories should monitor any devi-
ation from established performance characteristics in terms of 
quality metrics and analysis results. For any deviation, labora-
tories should document the investigational measures and correc-
tive actions made to resolve the deviation. Essential quality met-
rics for bioinformatics performance verification include depth of 
coverage, uniformity of coverage and base call quality scores. In 
addition, GC bias, proportion of reads that map to nontargeted 
regions, and percentage of duplicated reads could also be used 
to monitor performances of sequencing reaction and subsequent 
bioinformatics analyses (Table 5). 
Policies: upgrades, storage, and data management
The bioinformatics pipeline should be revalidated upon any 
changes in operating systems, software, or overall pipelines, 
which may otherwise affect its analytic performance. Since a 
huge amount of data files are generated from the bioinformatics 
pipeline, it is impractical to store all sorts of files considering the 
significant cost. Instead, the CAP NGS workgroup recommended 
that some important file formats, such as FASTQ, BAM, and 
VCF, should be stored for quality controls or investigational 
use.3 There is no general agreement on the required storage 
period, but it is important for laboratories to set their own stor-
age policies in accordance with local or national requirements (if 
any) and inform clients of those policies.
CONCLUSION
Although the advancement of NGS technologies unraveled 
the genomic landscape of human malignancies and opened an 
era of genome-guided anti-cancer therapies, the complexity of 
NGS technologies made it especially difficult to set up regula-
tory or professional standards for assuring analytical validity of 
test results. In this report, the workgroup addressed general 
guidelines related to the test procedures and proposed require-
ments for clinical NGS cancer panel tests such as test valida-
tion, quality controls, reference materials and participation in 
PT or AA. Due to space limitations and the clinical implemen-
tation of NGS cancer panel tests being in its infancy, granular 
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details were not covered in this review and those details should 
be addressed in further publications. 
As clinical experiences accumulate and technologies evolve, 
more refined recommendations or guidelines could be pub-
lished in the near future. In addition, good clinical decision 
support systems or knowledge bases need to be developed to 
help patients in terms of benefits from personalized FDA-
approved or investigational therapies and prognostic informa-
tion. To realize personalized cancer medicine in the end, it is 
important for medical communities to share information on 
genotype (oncogenic variants in patients’ samples)–phenotype 
(drug response or prognosis) relationships, and all these efforts 
start with accurate genomic profiling of cancer tissue. To ensure 
reliability of NGS-based genomic profiling, a multi-disciplinary 
team approach, involving clinicians, pathologists, laboratory 
scientists, bioinformaticians, manufacturers, professional orga-
nizations, and government agencies, is essential. 
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